| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435236000 | Inactivation or attenuation; producing viral subunits | 58 |
| 20080213863 | Method of Controlling Viral Outbreak - Disclosed is a novel application for β-cyclodextrin (β-CD, a cholesterol depletor), and a novel technique for the creation of immunogens. Topical application of β-CD inhibits or reduces the severity of viral outbreaks such as oral or genital herpes by disrupting lipid rafts, through which viral entry and outbreak occur. Viral entry involves virus/lipid raft interaction, wherein the virus unfolds—only in lipid rafts—to enter the cell via the lipid raft. The invention provides a technique for creating immunogens with novel viral epitopes based on the virus/lipid raft interaction and viral unfolding. This fact can be exploited to create novel immunogens based on viral interaction with lipid rafts. The virus/lipid raft co-culture technique creates novel immunogens which will be used to create novel neutralizing monoclonal and polyclonal antibodies to fight viral disease such as HIV infection. | 09-04-2008 |
| 20080241906 | Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same - The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof. | 10-02-2008 |
| 20080248551 | METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES - Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus. | 10-09-2008 |
| 20080318300 | Method for Inactivating Viruses With Slightly Acidic Arginine - The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. | 12-25-2008 |
| 20090004723 | Methods and Compositions Concerning Poxviruses and Cancer - The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer. | 01-01-2009 |
| 20090042273 | RECOVERY OF VIRUS FROM CELL CULTURE USING HYPERTONIC SALT SOLUTION - A process of harvesting a herpesvirus from a cell culture infected therewith comprises treating said culture with a hypertonic aqueous salt solution to yield a virus suspension, e.g. to give improved yield of virus for live virus vaccine where otherwise cell-disruption might be used to harvest the virus by disrupting virus-infected cells. The harvesting step can be followed e.g. by nuclease treatment, diafiltration and lyophilisation. | 02-12-2009 |
| 20090098634 | SCLEROPROTEIN OF AN ADENO ASSOCIATED VIRUS WITH MODIFIED CHROMATOGRAPHIC PROPERTIES, THE PRODUCTION THEREOF AND USE OF THE SAME - The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof. | 04-16-2009 |
| 20090246854 | SCLEROPROTEIN OF AN ADENO-ASSOCIATED VIRUS WITH MODIFIED CHROMATOGRAPHIC PROPERTIES, THE PRODUCTION THEREOF AND USE OF THE SAME - The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof. | 10-01-2009 |
| 20090246855 | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences - The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences. The invention also relates to chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. The invention further relates to vaccine formulations comprising mammalian or avian metapneumovirus, including recombinant and chimeric forms of said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. | 10-01-2009 |
| 20100075399 | METHODS FOR PROTEIN REFOLDING - The present invention discloses improved methods of disaggregating protein aggregates, and refolding denatured proteins, using high pressure. In particular, the present invention provides for the use of agitation, high temperature, “stepped” depressurization, dialysis and dilution under pressure to increase the speed and extent of aggregate dissolution and protein refolding. | 03-25-2010 |
| 20100099162 | NUCLEAR LOCALIZATION SIGNAL OF LENTIVIRAL INTEGRASE AND METHOD OF USE THEREOF - The present invention provides novel peptides, nucleic acids, vectors, compounds, compositions and methods for regulating nuclear import The present invention also relates to a lentiviral NLS, and methods of use thereof for inhibiting HIV pathogenesis and disease progression, and for gene delivery methods | 04-22-2010 |
| 20100105123 | SCLEROPROTEIN OF AN ADENO-ASSOCIATED VIRUS WITH MODIFIED CHROMATOGRAPHIC PROPERTIES, THE PRODUCTION THEREOF AND USE OF THE SAME - The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof. | 04-29-2010 |
| 20100167378 | PREPARATION OF VIRALLY INACTIVATED BIOLOGICAL FLUIDS HAVING HIGH ALPHA-2-ANTIPLASMIN ACTIVITY - The invention relates to the use of polyoxyethylene (4-5) p-t-octyl phenol (t-Oct-C | 07-01-2010 |
| 20100196993 | PERSISTENTLY INFECTIVE SENDAI VIRUS VECTOR - A persistently infective virus vector is produced by using a gene so modified as to encode an amino acid sequence including a valine substituted for an amino acid residue at position-1618 in the amino acid sequence for an L protein of a persistently non-infective Sendai virus. A non-transmissible, persistently infective virus vector is also produced by defecting or deleting at least one of M gene, F gene, and HN gene. These virus vectors have no cytotoxicity, can achieve the sustained gene expression over a long period of time, is safe, and is therefore useful. | 08-05-2010 |
| 20100233785 | NOVEL METHODS AND INTERFERON DEFICIENT SUBSTRATES FOR THE PROPAGATION OF VIRUSES - The present invention relates, to novel methods and substrates for the propagation of viruses. The invention relates to IFN-deficient substrates and methods for propagating viruses in these unconventional substrates. In particular, the invention relates to methods of propagating viruses in immature embryonated eggs, preferably six- to nine-day-old chicken eggs. The methods of the invention are particularly attractive for growing viruses suitable for use in vaccine and pharmaceutical formulations. | 09-16-2010 |
| 20110020908 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMA VIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 01-27-2011 |
| 20110070624 | MICROWAVE RESONANT ABSORPTION METHOD AND DEVICE FOR VIRUSES INACTIVATION - Virus inactivation is performed with a specific microwave frequency to induce a collective vibration of virus through microwave resonant absorption (MRA). | 03-24-2011 |
| 20110143424 | RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENE THERAPY - The invention provides compositions and methods useful to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs and in the absence of helper virus. | 06-16-2011 |
| 20120115206 | NON-TUMORIGENIC MDCK CELL LINE FOR PROPAGATING VIRUSES - The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention. | 05-10-2012 |
| 20120276614 | PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. | 11-01-2012 |
| 20120282673 | FUNCTIONAL MUTATION IN RESPIRATORY SYNCYTIAL VIRUS - The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided. | 11-08-2012 |
| 20130040370 | Novel Method for Vacuum-Assisted Preservation of Biologics Including Vaccines - The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for vitrifying biological preparations, including peptides, antigens, antibodies, cells, and the like. | 02-14-2013 |
| 20130052718 | ATTENUATED HUMAN PARAINFLUENZA VIRUS, METHODS AND USES THEREOF - The invention provides self replicating infectious recombinant paramyxoviruses. The recombinant paramyxovirus preferably have one or more attenuating mutations. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein. In some embodiments, recombinant paramyxovirus have at least one temperature sensitive mutation and one non-temperature sensitive mutation. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein. | 02-28-2013 |
| 20130273636 | DEPLETION OF HOST CELL COMPONENTS FROM LIVE VECTOR VACCINES - It is desirable to produce live vaccines, which are highly attenuated and which do only contain minimal or no animal-derived components. The production of highly attenuated live viruses can be better achieved when using specifically designed cell lines as producer substrate as opposed to using less defined primary cells. However, live viruses, thus produced comprise undesirable components from the cell lines and cell culture. The present invention relates to methods of production and purification of live enveloped viruses, which are suitable for vaccination. | 10-17-2013 |
| 20130288339 | PURIFICATION OF VACCINIA VIRUSES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY - The present invention relates to methods for purification of Vaccinia viruses (VV) and/ or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production. | 10-31-2013 |
| 20130323817 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF RECOMBINANT VIRUS VECTORS - A method for the production of a replication-deficient recombinant virus vector is disclosed. The replication-deficient recombinant virus vector has a recombinant virus genome with one or more defective viral genes. The method comprises infecting a host cell with a carrier virus having a carrier virus genome encoding one or more trans factors or variants thereof, incubating the infected host cell for a desired period of time, and isolating the replication-deficient recombinant virus vector. The carrier virus is a cytoplasmic virus that retains the carrier virus genome in the cytoplasm of the host cell. The host cell contains the recombinant viral genome and retains the recombinant viral genome in a nucleus of the host cell. Also disclosed is a carrier virus for the production of a replication-deficient recombinant virus vector. | 12-05-2013 |
| 20130344570 | METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS - The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized. | 12-26-2013 |
| 20140030792 | Therapeutic Anti-Virus VLPS - This invention provides therapeutic viruses (TV) and methods to inhibit the propagation of a target virus. TVs can be rendered noninfectious by inactivating mutations, but also include sequences providing miRNA to inactivate essential mRNAs of the target virus. Methods can include provision of the TV and contact with a host cell harboring the target virus. The target virus providing the essential enzymes necessary to the replication of the TV and the TV disabling the target virus with the miRNA. | 01-30-2014 |
| 20140045245 | REPLICATION DEFICIENT INFLUENZA VIRUS FOR THE EXPRESSION OF HETEROLOGOUS SEQUENCES - The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided. | 02-13-2014 |
| 20140220660 | PROCESS FOR THE PRODUCTION OF FILAMENTOUS BACTERIOPHAGE - The invention relates to culture conditions and methods that allow reproducible production of high titers of filamentous bacteriophage. Culture media comprising high titers of filamentous bacteriophage, as we methods of producing high titers of filamentous phage on a large scale are encompassed. | 08-07-2014 |
| 20140242669 | PRODUCTION OF INFECTIOUS RNA VIRUSES IN YEAST - The method described herein provides a novel platform utilizing yeast as a biological non-host system to express and assemble whole viruses for use as attenuated or killed vaccines. | 08-28-2014 |
| 20140242670 | PRODUCTION OF POLIOVIRUS AT HIGH TITERS FOR VACCINE PRODUCTION - Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E | 08-28-2014 |
| 20140356930 | IMMUNE SYSTEM ENHANCING IMMUNOTHERAPY FOR THE TREATMENT OF CANCER - This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer. | 12-04-2014 |
| 20150118732 | GENETICALLY STABLE LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE AND ITS PRODUCTION - Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use. | 04-30-2015 |
| 20150337269 | METHODS FOR INACTIVATION OF VIRUSES AND BACTERIA IN CELL CULTURE MEDIA - The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized. | 11-26-2015 |
| 20160053233 | METHOD FOR TERMINAL INACTIVATION OF PATHOGENIC MICROORGANISMS - The present invention discloses a method for terminal inactivation of pathogenic microorganisms, comprising the following steps of: a. vacuum freeze-drying a bio-product packaged in a container, feeding in a gas and sealing to obtain the end product and, b. performing inactivation by dry-heating. The method provided by the present invention can effectively inactivate non-lipid enveloped viruses, with excellent inactivation effects and short inactivation time particularly to parvoviruses, and thus overcome the deficiencies of the conventional terminal dry-heating inactivation methods. | 02-25-2016 |
| 20160122728 | IPN VACCINE - The present invention relates to a live avirulent infectious pancreatic necrosis virus which has been shown to be genetically stable in biological studies. Fish exposed to said virus turn out positive for the virus without showing any signs of disease and the avirulent virus has also been shown to protect the fish against IPN for an extended period of time after administration. Thus, a vaccine comprising said virus and said virus for the prophylaxis or treatment of infectious pancreatic necrosis disease are also part of the present invention. | 05-05-2016 |
| 435237000 | By serial passage of virus | 3 |
| 20090162918 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 06-25-2009 |
| 20120009654 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 01-12-2012 |
| 20130089913 | METHOD FOR THE CULTIVATION OF PRIMARY CELLS AND FOR THE AMPLIFICATION OF VIRUSES UNDER SERUM FREE CONDITIONS - The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced. | 04-11-2013 |
| 435238000 | By chemical treatment | 18 |
| 20080274534 | Virus Filtration of Liquid Factor VII Compositions - The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide). | 11-06-2008 |
| 20080286849 | Herbal extract having anti-virus activity and preparation of same - The invention relates to the herbal extract having anti-viral activity. More specifically, it relates to the herbal extract produced by extracting the comminuted Fructus Ligustri Lucidi (privet fruit), Rhizoma Polygonati (sealwort), Herba Agrimoniae (agrimonia), Radix Rehmanniae Glutinosae Conquitae (steamed glutinous rehmannia) or the mixture thereof, with a low polar solvent, and to the method for in vitro antagonizing virus by contacting the herbal extract with viruses. | 11-20-2008 |
| 20100021989 | COMPOSITIONS AND METHODS OF CONTROLLING AND ADMINISTERING REDOX SPECIFIC FORMS OF DRUGS, FOODS AND DIETARY SUPPLEMENTS - The formulations have an antimicrobial, antiviral, and anti-pathogenic composition that combines, in various forms, a redox-active polyphenol, an oxidizing agent, and/or a redox-active, transition metal ion and/or electrochemical potential. The composition relates to methods for decreasing or eliminating the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for treating herpes simplex and HIV viruses and drug-resistant bacteria, and for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods, compositions, electrochemical devices, and storage containers for decreasing the infectivity of pathogenic organisms in pharmaceuticals, medical devices, personal care products, recreational products, and foodstuffs. | 01-28-2010 |
| 20100047897 | Process for producing modified reconstituted sendai viral envelope specific for drug and/or gene delivery to liver cells - A process for producing a targeted gene and/or drug delivery system for liver cells comprising the steps of: i. chemical reduction of Sendai virus for reduction of HN protein; ii. subjecting the reduced virus to the step of dialysis for removal of the reducing agent; iii. solubilizing the reduced virus with a detergent to obtain a solution; iv. centrifuging the solution to separate the insolubles consisting of reduced HN protein and core of said virus; v. adding histidylated lipid to the supernatant; vi. adding the drug or gene after addition of the lipid; vii. removing the detergent from the envelope and then subjecting it to the step of centrifugation to obtain His lipid F-virosomes with entrapped drug or DNA. | 02-25-2010 |
| 20100129893 | OPTIMAL PLACEMENT OF A ROBUST SOLVENT/DETERGENT PROCESS POST VIRAL ULTRAFILTRATION OF AN IMMUNE GAMMA GLOBULIN - The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1.0% detergent and 0.3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation, which required significantly reduced concentrations of solvent and detergent. Reduced levels of solvent and detergent lead to greater efficiencies in their removal post-inactivation with the potential for greater yields and decreased processing costs. | 05-27-2010 |
| 20110136210 | USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY - Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production of beer, cider, wine, a biofuel, dairy product or any combination thereof. Also disclosed are in vitro methods for enhancing the growth of one or more probiotic microorganisms and methods of enhancing growth of a microorganism in a diagnostic test sample. Methods of inhibiting microbial activity are also disclosed. In one particular example, a method of inhibiting microbial activity includes selecting a medium that is susceptible to H1N1 influenza contamination; and contacting the medium with MSM at a concentration of about 10% to about 16% of weight by volume, thereby inhibiting H1N1 influenza microbial activity. | 06-09-2011 |
| 20120015424 | Arginine Inactivation of Viruses - The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment. | 01-19-2012 |
| 20120034678 | Diaryl Ethers - Compounds of the formula I: | 02-09-2012 |
| 20120058539 | METHOD FOR ORTHOPOXVIRUS PRODUCTION AND PURIFICATION - The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular | 03-08-2012 |
| 20130102054 | SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATION FROM AN EXTERIOR SOURCE - A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent. | 04-25-2013 |
| 20130203152 | Method for Reducing DNA Impurities in Viral Compositions - A method for purification of viral compositions is provided. In particular, a method for reduction of unwanted residual DNA in a viral composition while retaining the immunogenicity of the virus itself is provided. The resulting immunogenic viral composition is substantially free of residual DNA, and is useful for the manufacture of medical products, such as vaccines designed for human or animal. | 08-08-2013 |
| 20130280788 | CHROMATOGRAPHY METHOD - The present invention is directed to a continuous affinity chromatography method and to an apparatus to be used in such method. The method allows the use of high operational velocity while maintaining high binding capacities. | 10-24-2013 |
| 20140256019 | Compositions and Methods for Inhibiting Viral Adhesion - The present invention provides compositions and methods for treating or preventing viral infections. | 09-11-2014 |
| 20140315277 | NOVEL METHOD - The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuclease and ii) a DNA alkylating agent. | 10-23-2014 |
| 20150064768 | Systems and Methods for Virus Propagation in Cell Cultures for Vaccine Manufacture - The present invention provides a closed system to propagate virus-infected cells without the effect of shear force, while providing quicker access to nutrients than is available conventionally. This system design allows for a high density of infected cell growth to increase the virus yields and to maintain homogeneity of the contents of the main container. The system further provides a nuclease to degrade the cellular DNA prior for purification of the virus or viral components. As the system is designed for maximum containment at low risk, the live virus can be a hazardous virus such as a Bio-safety Level 3 (BSL 3), BSL 4 or BSL5 virus. | 03-05-2015 |
| 20150064769 | Methods for Inactivating Viruses During a Protein Purification Process - The present application relates to novel and improved methods of achieving virus inactivation during a protein purification process. | 03-05-2015 |
| 20160010063 | ARGININE INACTIVATION OF VIRUSES | 01-14-2016 |
| 20160101215 | PREPARATION METHOD FOR IMPLANTABLE MEDICAL BIOLOGICAL MATERIALS OF ANIMAL ORIGIN - The present invention provides a preparation method for implantable medical biological material of animal origin comprising the following procedures: Pre-processing, and washing of animal tissue materials; inactivation of virus; decellularizing cell; sodium chloride processing; molding and packaging sterilization. Cell-free ECM materials of animal origin produced by this method can achieve the goal of completely removing cell components of animal origin and composition of DNA, and at the same time, the natural ECM composition, three-dimensional structure and active growth factor which can induce and promote tissue regeneration retain. By using this process, endotoxin, organic solvents and toxic solvent residue are thus omitted and products with different sizes, thickness and mechanical strength can be formed. | 04-14-2016 |
